Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs
Provided By PR Newswire
Last update: Jun 11, 2025
SAN DIEGO and CALGARY, AB, June 11, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Jared Kelly as Chief Executive Officer and a member of its Board of Directors.
Read more at prnewswire.com
